Pat Garcia-Gonzalez, Chief Executive Officer at The Max Foundation, shared a post on LinkedIn:
“I remember vividly a day in the early 90’s when I had what could be called a premonition. I suddenly knew that someday I would witness the development of a medicine that would have saved Max. That day came 25 years ago on May 11th, 2001. Little did I know then that I would be at the center of an amazing movement to bring this medicine and so many others to people around the world.
I’m honored to join an exceptional group of leaders who made that possible for an upcoming webinar: “Max Insights: 25 Years of CML Treatment Innovation.” We’ll reflect on the breakthroughs that have transformed CML from a fatal diagnosis into a manageable disease for many, along with the work that’s still ahead to ensure access for all.
Together, we’ll explore:
- The birth of targeted therapy
- The evolution of access to cancer medicines
- What it will take to ensure people living with CML can get the treatments they need
This conversation will bring together perspectives from research, advocacy, and global access. Together we’ll examine how science and patient‑centered advocacy have reshaped the CML landscape over the past 25 years, and what continued progress will require.
I’m especially proud to be part of this discussion alongside:
Paula Boultbee, Board Member, The Max Foundation
Brian Druker, President, Oregon Health and Science University, Knight Cancer Institute
Jan Geissler, Co‑Founder, CML Advocates Network
Dr. Jerry Radich, board member of The Max Foundation, professor and clinical researcher at Fred Hutch
If you care about the future of cancer innovation and equitable access, I hope you’ll join.
Other articles featuring Pat Garcia-Gonzalez on OncoDaily.